This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Imbruvica
  • /
  • A Randomized, Controlled, Open-Label, Multicenter ...
Clinical trial

A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Read time: 2 mins
Last updated:1st Dec 2012
Identifier: NCT01646021
The purpose of this study is to evaluate the efficacy and safety of ibrutinib versus temsirolimus in patients with relapsed or refractory mantle cell lymphoma who received at least 1 prior chemotherapy regimen.
Category Value
Date last updated at source 2017-01-11
Study type(s) Interventional
Expected enrolment 280
Study start date 2012-12-01
Estimated primary completion date 2016-12-01

View full details